Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (ESPR) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ESPR · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
17
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Esperion Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
ESPR insider buying and selling by quarter
ESPR insider selling · ESPR insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · ESPR ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
ESPR executive sell shares · ESPR board member insider trading · ESPR insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 28, 2026 | THOMPSON JOHN CRAIG Director | Award | 79,873 | — | Form 4 |
| May 28, 2026 | Shepard Jay Director | Award | 79,873 | — | Form 4 |
| May 28, 2026 | Hoffman Robert E. Director | Award | 79,873 | — | Form 4 |
| May 28, 2026 | Fischer Seth H. Z. Director | Award | 79,873 | — | Form 4 |
| May 28, 2026 | CARROLL J MARTIN Director | Award | 79,873 | — | Form 4 |
| Mar 17, 2026 | Looker Benjamin Chief Legal Officer | Sale | 5,708 | $15K | Form 4 |
| Mar 17, 2026 | Koenig Sheldon L. President and CEO · Director | Sale | 25,578 | $70K | Form 4 |
| Mar 17, 2026 | Halladay Benjamin CFO | Sale | 6,424 | $17K | Form 4 |
| Mar 13, 2026 | Looker Benjamin Chief Legal Officer | Award | 300,840 | — | Form 4 |
| Mar 13, 2026 | Koenig Sheldon L. President and CEO · Director | Award | 723,760 | — | Form 4 |
| Mar 13, 2026 | Halladay Benjamin CFO | Award | 247,430 | — | Form 4 |
| Jan 20, 2026 | Looker Benjamin General Counsel | Sale | 1,689 | $5K | Form 4 |
| Dec 17, 2025 | Koenig Sheldon L. President and CEO · Director | Sale | 48,244 | $177K | Form 4 |
| Dec 17, 2025 | Halladay Benjamin CFO | Sale | 7,337 | $27K | Form 4 |
| Dec 17, 2025 | Looker Benjamin General Counsel | Sale | 6,517 | $24K | Form 4 |
| Dec 4, 2025 | Harlow John B. Jr. Chief Commercial Officer | Award | 424,536 | — | Form 4 |
| Sep 17, 2025 | Looker Benjamin General Counsel | Sale | 6,267 | $18K | Form 4 |
| Sep 17, 2025 | Koenig Sheldon L. President and CEO · Director | Sale | 28,427 | $79K | Form 4 |
| Sep 17, 2025 | Halladay Benjamin CFO | Sale | 7,046 | $20K | Form 4 |
| Jul 17, 2025 | Looker Benjamin General Counsel | Sale | 1,304 | $1K | Form 4 |
| Jul 17, 2025 | Halladay Benjamin CFO | Sale | 11 | $12 | Form 4 |
| Jun 17, 2025 | Looker Benjamin General Counsel | Sale | 6,422 | $7K | Form 4 |
| Jun 17, 2025 | Koenig Sheldon L. President and CEO · Director | Sale | 30,474 | $34K | Form 4 |
| Jun 17, 2025 | Halladay Benjamin CFO | Sale | 7,229 | $8K | Form 4 |
| May 29, 2025 | CARROLL J MARTIN Director | Award | 33,000 | — | Form 4 |
Looker Benjamin
Chief Legal Officer
Date
Mar 17
Shares
5,708
Price
$2.70
Value
$15K
Koenig Sheldon L.
President and CEO · Director
Date
Mar 17
Shares
25,578
Price
$2.72
Value
$70K
Koenig Sheldon L.
President and CEO · Director
Date
Mar 13
Shares
723,760
Price
—
Value
—
Koenig Sheldon L.
President and CEO · Director
Date
Dec 17
Shares
48,244
Price
$3.67
Value
$177K
Harlow John B. Jr.
Chief Commercial Officer
Date
Dec 4
Shares
424,536
Price
—
Value
—
Koenig Sheldon L.
President and CEO · Director
Date
Sep 17
Shares
28,427
Price
$2.79
Value
$79K
Koenig Sheldon L.
President and CEO · Director
Date
Jun 17
Shares
30,474
Price
$1.11
Value
$34K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ESPR insider trading
ESPR insider trades
Esperion Therapeutics, Inc. (ESPR) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Looker Benjamin (Chief Legal Officer), Halladay Benjamin (CFO), Koenig Sheldon L. (President and CEO · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. ESPR insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Esperion Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ESPR insider trading · 5 questionsThe insiders of Esperion Therapeutics, Inc. (ESPR) include executives and directors such as Looker Benjamin (Chief Legal Officer), Halladay Benjamin (CFO), Koenig Sheldon L. (President and CEO · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026